Drug Database · Clinicians

Hydralazine

Brands (11) Aprezal, Aprezin, Aprezobas…Show all

US brand (reference label): Hydralazine Hydrochloride; not a Philippine-registered brand.

Antihypertensive (hydrazinophthalazine derivative); Direct vasodilator; and others PH FDA category

Rx · Prescription drug13 PH productsPNF-listedVAT-exempt (some products)
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 8223c44a-73a9-4da5-a468-d1d8bdb0bbd6, version date October 7, 2026 (Hydralazine Hydrochloride · Fresenius Kabi USA, LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • INDICATIONS AND USAGE: Severe essential hypertension when the drug cannot be given orally or when there is an urgent need to lower blood pressure.
US FDA label
Full indications and usage US FDA label

INDICATIONS AND USAGE: Severe essential hypertension when the drug cannot be given orally or when there is an urgent need to lower blood pressure.

Contraindications

CONTRAINDICATIONS: Hypersensitivity to hydralazine, coronary artery disease, mitral valvular rheumatic heart disease.

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

DOSAGE AND ADMINISTRATION: When there is urgent need, therapy in the hospitalized patient may be initiated intramuscularly or as a rapid intravenous bolus injection directly into the vein. Hydralazine Hydrochloride Injection should be used only when the drug cannot be given orally. The usual dose is 20 to 40 mg, repeated as necessary.

Certain patients (especially those with marked renal damage) may require a lower dose. Blood pressure should be checked frequently. It may begin to fall within a few minutes after injection, with the average maximal decrease occurring in 10 to 80 minutes. In cases where there has been increased intracranial pressure, lowering the blood pressure may increase cerebral ischemia.

Most patients can be transferred to oral hydralazine hydrochloride within 24 to 48 hours. The product should be used immediately after the vial is opened. The product should not be added to infusion solutions. Hydralazine Hydrochloride Injection may discolor upon contact with metal; discolored solutions should be discarded.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Dosing: Altered kidney function

From the US FDA label · Dosage and administration (renal excerpts)

Certain patients (especially those with marked renal damage) may require a lower dose.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosage forms

Philippines

  • Solution for injection: 20 mg/mL
  • Film-coated tablet: 25 mg, 50 mg

Registered products in the Philippines

13 products registered with the Food and Drug Administration (FDA) Philippines list Hydralazine as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Also registered under: Hydralazine HCI (1 product). Products registered under these spellings are included in the table and marked.

Verify on PH FDA portal

All registered products13
Philippine FDA-registered products for Hydralazine
Package insert
AprezalHydralazine Hydrochloride
20 mg/mL Solution for Injection (I.M./I.V.)Type I amber colored glass ampoule x 1 mL (Box of 10's)
RxVAT-exempt
Kwality Pharmaceuticals LimitedIndia
Phil Pharmawealth, Inc.
DR-XY40652
Feb 16, 2027
AprezinHydralazine hydrochloride
25 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Pharmasant Laboratories Co., Ltd.Thailand
Endure Medical, Inc.
DR-XY36017
Jun 23, 2027
AprezobasHydralazine Hydrochloride
20 mg/mL Solution for Injection (IM/IV)In 1 mL Clear, Colorless USP Type I Glass Ampoule (Box of 10's)
RxVAT-exempt
Friends Pharma (Pvt.) Ltd.Pakistan
Raquel-Abbas Pharmaceuticals & General Merchandise
DRP-9972
Mar 12, 2031
CardiwonHydralazine Hydrochloride
20 mg/mL Solution for Injection (IM/IV)USP Type I Amber Glass Ampoule x 1mL in a plastic tray x 10's (Box of 10's) Box of 10's
RxVAT-exempt
Nitin Lifesciences Ltd.India
Seapharma International, Inc.
DRP-6668
Apr 27, 2031
H-WellHydralazine hydrochloride
20 mg/mL Solution for Injection (IM/IV)USP Type I Amber glass ampoule x 1 mL (Box of 10's)
RxVAT-exempt
Pharmax India Private LimitedIndia
Wellchem Pharmaceutical Products
DRP-16852
Jul 18, 2030
HydralexHydralazine hydrochloride
20 mg/mL Solution for Injection (IM/IV)Type I Amber Glass Ampoule x 1 mL (Box of 10's)
RxVAT-exempt
Farbe Firma Pvt. Ltd.India
AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc.
DRP-14599
Oct 25, 2028
Hydrazinesaph-AltHydralazine HCIVariant spelling
20 mg/mL Solution For Injection (IM/IV)Type I Amber Glass Ampoule in PVC Tray x 1 mL (Box of 5's and 10's)
Rx
Althea Pharma Pvt. Ltd.India
Nelpa Lifesciences, Inc.
DRP-19022
Oct 19, 2031
HyperzineHydralazine hydrochloride
20 mg/mL Solution for Injection (IM/IV)1 mL USP Type 1 amber colored glass ampoule (Box of 10's)
RxVAT-exempt
Medchem International LimitedIndia
Pharma-Surrey International, Inc.
DRP-4130
Dec 3, 2027
NoneHydralazine Hydrochloride
50 mg Film-Coated TabletAluminum Foil Strip x 10's (Box of 100's)
RxVAT-exempt
Drugmaker's Laboratories, Inc.Philippines
—
DR-XY24589
Oct 6, 2028
SapharinHydralazine Hydrochloride
20 mg/mL Solution for Injection (IM/IV)1 mL USP Type I amber ampoule with purple ring in transparent plastic tray (Box of 10's)
RxVAT-exempt
Kilitch Drugs (India) Ltd.India
Nelpa Lifesciences, Inc.
DRP-11246
Feb 21, 2027
Saphdrazin-B20Hydralazine hydrochloride
20 mg/mL Solution For Injection (IM/IV)Type I Amber Glass Ampoule x 1 mL (Box of 5's and 10's)
RxVAT-exempt
Belco PharmaIndia
Ollen Pharma Trading Inc.
DRP-18961
Oct 7, 2031
ZinlonHydralazine Hydrochloride
20 mg/mL Solution for Injection (I.M/I.V.)USP Type I Amber Glass Ampoule (Box of 10's)
RxVAT-exempt
Norris Medicines LimitedGujarat India
Vivilon Pharmaceuticals Inc.Importer: Medethix, Inc.Trader: Alvita Pharma Private Limited
DRP-4780-01
Aug 11, 2031
(no brand name)Hydralazine Hydrochloride
20 mg/mL Solution for InjectionType I Amber Colored Ampoule x 1 mL (Box of 10's)
RxVAT-exempt
Ciron Drugs & Pharmaceuticals Pvt. LimitedIndia
Phil Pharmawealth, Inc.
DR-XY26260
Mar 26, 2030

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

Warnings and precautions (US label) US FDA label

WARNINGS: In a few patients, hydralazine may produce a clinical picture simulating systemic lupus erythematosus including glomerulonephritis. In such patients, hydralazine should be discontinued unless the benefit-to-risk determination requires continued antihypertensive therapy with this drug. Symptoms and signs usually regress when the drug is discontinued but residua have been detected many years later. Long-term treatment with steroids may be necessary (see PRECAUTIONS, Laboratory Tests).

Adverse reactions

Adverse reactions (US label) US FDA label

ADVERSE REACTIONS: To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Adverse reactions with hydralazine hydrochloride are usually reversible when dosage is reduced. However, in some cases it may be necessary to discontinue the drug. The following adverse reactions have been observed, but there has not been enough systematic collection of data to support an estimate of their frequency.

Common: Headache, anorexia, nausea, vomiting, diarrhea, palpitations, tachycardia, angina pectoris. Less Frequent: Digestive -constipation, paralytic ileus. Cardiovascular -hypotension, paradoxical pressor response, edema. Respiratory -dyspnea. Neurologic -peripheral neuritis, evidenced by paresthesia, numbness, and tingling; dizziness; tremors; muscle cramps, psychotic reactions characterized by depression, disorientation, or anxiety.

Genitourinary -difficulty in urination. Hematologic -blood dyscrasias, consisting of reduction in hemoglobin and red cell count, leukopenia, agranulocytosis, purpura; lymphadenopathy; splenomegaly. Hypersensitive Reactions -rash, urticaria, pruritis, fever, chills, arthralgia, eosinophilia, and, rarely, hepatitis. Other -nasal congestion, flushing, lacrimation, conjunctivitis.

Pharmacokinetics

Pharmacokinetics (US label) US FDA label

CLINICAL PHARMACOLOGY: Although the precise mechanism of action of hydralazine is not fully understood, the major effects are on the cardiovascular system. Hydralazine apparently lowers blood pressure by exerting a peripheral vasodilating effect through a direct relaxation of vascular smooth muscle. Hydralazine, by altering cellular calcium metabolism, interferes with the calcium movements within the vascular smooth muscle that are responsible for initiating or maintaining the contractile state.

The peripheral vasodilating effect of hydralazine results in decreased arterial blood pressure (diastolic more than systolic); decreased peripheral vascular resistance; and an increased heart rate, stroke volume and cardiac output. The preferential dilatation of arterioles, as compared to veins, minimizes postural hypotension and promotes the increase in cardiac output.

Hydralazine usually increases renin activity in plasma presumably as a result of increased secretion of renin by the renal juxtaglomerular cells in response to reflex sympathetic discharge. This increase in renin activity leads to the production of angiotensin II, which then causes stimulation of aldosterone and consequent sodium reabsorption.

Hydralazine also maintains or increases renal and cerebral blood flow. The average maximal decrease in blood pressure usually occurs 10 to 80 minutes after administration of hydralazine hydrochloride injection. No other pharmacokinetic data on hydralazine hydrochloride injection are available.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Hydralazine 20 mg/mL, 1 mL Ampule₱18.77–₱180.00Reference ₱27.88per ampuleDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Hydralazine (as hydrochloride)
PNF listingOral: 25 mg and 50 mg tablet
PNF listingInj.: 20 mg/mL, 1 mL ampul (IM, IV)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Hydralazine Hydrochloride · Fresenius Kabi USA, LLC [US FDA-approved label, version 13, October 7, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8223c44a-73a9-4da5-a468-d1d8bdb0bbd6
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .